Hyperliquid Crosses 7% of Exchange Perp Volume for the First Time
Hyperliquid’s share of all exchange perpetual volume has hit a new high, pushing past the 7% mark since inception and reaching 7.6% as of June 8, according to The Block. While the field is still dominated by tier 1 centralized exchanges like Binance, Bybit and OKX, the DEX platform is certainly in an uptrend in this regard ever since December.
The timing itself is more significant than the figure. Total crypto market cap is down nearly 26% year to date and the sell off has only accelerated over the past week with Bitcoin testing new yearly lows of $59k on June 5. This is the kind of stretch where a newer platform usually hands share back to the incumbents. Hyperliquid has thus far done the reverse.
Measured Against Everything, Not Just the DEXs
Throughout the year, Hyperliquid has held market dominance over perp DEX volumes. The platform started the year with a 23.75% market share, which has now grown to 56.31%. The 7.6% data is a different yardstick altogether. This is a number against some of the largest centralized giants that continue to move most of the market.
Hyperliquid is taking share from some of the legacy names in the space at a time when there have been some notable headwinds for the project. Most notably on June 4, Arthur Hayes, the BitMEX co-founder known for his macro market calls, disclosed that he had closed his entire HYPE position that was reportedly worth around $18 million. Hayes saw the exit as a macro top call because of energy-driven inflation from the Iran conflict and a series of AI IPOs that could pull liquidity toward equities. This took place just days after his bullish stance on HYPE.
HYPE’s price dropped roughly 10% amid a broader market sell off. Despite the token being down nearly 15% on the week, the platform itself did something entirely different. Even as the token saw a decline, volume continued flowing through the platform. The price of HYPE and the usage of Hyperliquid moved in opposite directions and that gap is the actual story here.
Why the Share Gains Look Structural
Share that holds up in a downturn reads very differently from share bought with incentives. Trading volume tends to concentrate on whichever venue offers the best execution and liquidity when conditions get rough. If Hyperliquid were running on points-farming and airdrop expectations, a sell off this sharp is exactly when that activity would thin out. It did not. The platform kept pulling flow precisely as capital turned cautious.
That is the case for calling these gains structural rather than froth. Incentive-driven volume evaporates under stress. Volume that grows under stress usually comes from traders who want the product, not the rewards.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
